# ROSETTA CRC-203 (NCT07221357)

> A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07221357
- Phase: PHASE2, PHASE3
- Status: RECRUITING
- Sponsor: Bristol-Myers Squibb
- Conditions: Untreated, Unresectable, or Metastatic Colorectal Cancer
- Interventions: Pumitamig; FOLFOX; FOLFIRI; Bevacizumab; CAPOX
- Enrollment: 990
- Primary outcome: Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment
- Primary outcome: Progression Free Survival (PFS) by RECIST v1.1 per blinded independent central review (BICR)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on ROSETTA CRC-203 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 post on Bluesky

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=rosetta-crc-203-nct07221357